Dearborn Partners LLC Reduces Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Dearborn Partners LLC lowered its stake in iShares Biotechnology ETF (NASDAQ:IBB) by 8.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,561 shares of the financial services provider’s stock after selling 499 shares during the quarter. Dearborn Partners LLC’s holdings in iShares Biotechnology ETF were worth $735,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sigma Planning Corp lifted its holdings in iShares Biotechnology ETF by 11.7% in the 3rd quarter. Sigma Planning Corp now owns 7,083 shares of the financial services provider’s stock valued at $1,031,000 after purchasing an additional 743 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of iShares Biotechnology ETF during the third quarter valued at approximately $36,000. Aptus Capital Advisors LLC boosted its position in iShares Biotechnology ETF by 36.5% during the third quarter. Aptus Capital Advisors LLC now owns 426 shares of the financial services provider’s stock worth $62,000 after acquiring an additional 114 shares during the last quarter. Oppenheimer & Co. Inc. grew its stake in iShares Biotechnology ETF by 0.7% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 35,663 shares of the financial services provider’s stock worth $5,193,000 after acquiring an additional 237 shares during the period. Finally, Main Street Financial Solutions LLC grew its stake in iShares Biotechnology ETF by 1.9% in the 3rd quarter. Main Street Financial Solutions LLC now owns 8,152 shares of the financial services provider’s stock worth $1,187,000 after acquiring an additional 150 shares during the period. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Down 1.4 %

Shares of iShares Biotechnology ETF stock opened at $133.99 on Wednesday. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57. The business’s fifty day moving average is $136.20 and its two-hundred day moving average is $140.05. The firm has a market cap of $6.33 billion, a PE ratio of 24.52 and a beta of 0.84.

iShares Biotechnology ETF Cuts Dividend

The firm also recently announced a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were given a dividend of $0.0624 per share. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.